Durvalumab vs Potassium Citrate Anhydrous

## Durvalumab vs Potassium Citrate Anhydrous: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Potassium Citrate Anhydrous**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Potassium Citrate Anhydrous — N/A.

## Chemical Properties

**Type**: Durvalumab — Antibody; Potassium Citrate Anhydrous — Small molecule.